Lyrica Generics Likely Delayed By A Pfizer Labeling Supplement
Executive Summary
US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.
You may also be interested in...
Generic Drug Sponsors Would Get More Info On Brand Inactive Ingredients Under User Fee Bill
PhRMA expresses concerns the provision would reveal trade secrets, but since the draft bill already has support from the Republican committee leadership, the brand industry may find it a challenge to get the language removed.
Generic Drug Sponsors Would Get More Info On Brand Inactive Ingredients Under User Fee Bill
PhRMA expresses concerns the provision would reveal trade secrets, but since the draft bill already has support from the Republican committee leadership, the brand industry may find it a challenge to get the language removed.
Holding ANDA Labeling Review Until Late Cycle Could Minimize Delays From Last-Minute Changes
A GDUFA III adjustment could allow more labeling changes during the review cycle and reduce assessment cycles.